At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 16 enrolled
Drug / intervention
Kybella 20 MG in 2 ML Injection +1 moredrug
Likely dose
Kybella 20 MG in 2 ML Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fat Reduction in the Submental Area - a Sequential Treatment Approach With CoolMini and KYBELLA®
In Brief
A Phase 4 clinical trial evaluating The ZELTIQ CoolSculpting System and Kybella 20 MG in 2 ML Injection for Body Fat Disorder. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Evaluate the safety and efficacy of subcutaneous fat layer reduction in the submental area using multiple therapeutic tools.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBody Fat Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedApr 27, 2018
Enrollment StartMar 27, 2018
Primary CompletionDec 8, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.2 years ago
Interventions
The ZELTIQ CoolSculpting Systemdevice
The CoolSculpting machine will be used to perform the treatments.
Kybella 20 MG in 2 ML Injectiondrug
Injectable drug called KYBELLA® (deoxycholic acid)